Eyenovia Showcases Clobetasol Study Achievements at AAO Expo
Eyenovia's Presentation at AAO 2024 Expo
Eyenovia, Inc. (NASDAQ: EYEN), a pioneering company in ophthalmic technology, is making waves in the medical community with its presentation at the prestigious AAO 2024 Expo. This significant event is set to take place from October 19 to 21 in Chicago, where experts from around the globe gather to share insights and advancements in the field of ophthalmology.
Exciting Study Results Revealed
The focal point of Eyenovia's presentation will be the groundbreaking results from their Phase 3 study, designated CPN-302. This study centers around clobetasol propionate suspension 0.05% (APP13007), which has recently garnered approval from the U.S. Food and Drug Administration. This approval is a landmark achievement, as it serves as a treatment strategy for managing inflammation and alleviating pain following ocular surgeries.
Launch and Commercial Availability
Eyenovia is enthusiastic about the recent U.S. launch of clobetasol, which commenced on September 26, 2024. The company recognizes the urgency of addressing post-surgical challenges and believes this product will significantly enhance patient care. Michael Rowe, the Chief Executive Officer of Eyenovia, expressed his excitement regarding the study's outcomes, indicating that these findings marked a new chapter in ophthalmic treatment.
Rapid Results and Enhanced Safety Profile
According to Mr. Rowe, the Phase 3 study not only demonstrated swift relief from inflammation and pain—within just four days post-surgery—but also highlighted rapid improvements in visual acuity. These promising results are further bolstered by a safety profile that is deemed desirable, ensuring that healthcare professionals can recommend clobetasol with confidence.
Presentation Highlights
Details of the presentation include:
- Title: Clobetasol Propionate Ophthalmic Suspension 0.05% (APP 13007) for the Treatment of Postsurgical Inflammation and Pain (Study CPN-302)
- Presenter: Dr. Jeffrey H Levenson from Levenson Eye Associates
- Date/Time: Available on-demand throughout the AAO Expo
About Eyenovia, Inc.
Eyenovia is committed to innovation in the ophthalmic domain, focusing on developing an advanced pipeline of products through its unique Optejet platform. The company continues to work on commercializing Mydcombi for pupil dilation, alongside further developing clobetasol for post-surgical treatment. Future endeavors also include the late-stage development of solutions for pediatric progressive myopia, along with exploring licensing opportunities for additional uses.
Contact Information
For those interested in learning more about Eyenovia or their presented products, the company can be contacted directly:
- Eyenovia Contact:
Andy Jones, Chief Financial Officer
Email: ajones@eyenovia.com - Eyenovia Investor Contact:
Eric Ribner, LifeSci Advisors, LLC
Email: eric@lifesciadvisors.com
Phone: (646) 751-4363 - Eyenovia Media Contact:
Norbert Lowe, Vice President, Commercial Operations
Email: nlowe@eyenovia.com
Frequently Asked Questions
What was the main focus of Eyenovia's presentation at AAO Expo?
The primary focus was on the results of the Phase 3 study of clobetasol propionate suspension 0.05%, highlighting its effectiveness for post-surgical inflammation and pain relief.
When was clobetasol launched?
Clobetasol was launched on September 26, 2024, marking a significant milestone for Eyenovia in terms of product availability.
Who presented the study at the expo?
The study was presented by Dr. Jeffrey H Levenson from Levenson Eye Associates.
How quickly can clobetasol relieve symptoms after surgery?
Patients can expect significant relief from inflammation and pain as soon as four days after surgery when using clobetasol.
What is Eyenovia's vision for their products in the market?
Eyenovia aims to position clobetasol as the preferred choice for post-operative care due to its effectiveness and safety profile.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Regions Foundation Allocates $200K for Hurricane Milton Relief Efforts
- Vicor Launches Innovative Power Modules for Automotive Needs
- Super Micro Innovates with Efficient Liquid-Cooled AI Solutions
- Join EverC's Safer Ecommerce Day to Combat Online Fraud
- Noco-noco Boosts Battery Production with X-SEPA Technology
- Revolutionizing Prostate Cancer Therapy with Copper-67
- Rathbones Group Plc's Position in Keywords Studios Explained
- NFL Stadiums Face Climate-Related Losses of Up to $11 Billion
- ACNB Corporation Declares Increased Quarterly Cash Dividend
- iFLYTEK Launches Revolutionary AINOTE Air 2 at Global Tech Event
Recent Articles
- Lifeist Wellness Concludes Partnership with Singular Narrative
- Birdseye Security Solutions Welcomes Investment from GreyLion
- Apogee Therapeutics to Showcase APG777 at ACAAI Conference
- Cathay Cargo and Descartes Ensure Safe Panda Transport
- PennyMac Mortgage Investment Trust Set to Announce Q3 2024 Results
- Pharvaris Unveils Key Findings on Deucrictibant at Meetings
- The RMR Group's Upcoming Conference Call Discussion Details
- U.S. Bancorp's Third Quarter Financial Insights Unveiled
- Global Market Insights: A Comprehensive Overview of Trends
- Yum China Celebrates Jannik Sinner's Triumph at Masters Tournament
- Nestle's New CEO Faces Investor Skepticism Amid Sluggish Growth
- HSBC Predicts Growth for S&P 500 Despite Low Earnings Outlook
- Major Contracts for Luxury Villas at Palm Jebel Ali Unveiled
- Omnicom Group's Robust Q3 Growth Sparks Future Optimism
- Telecom Network APIs Expected to Generate $9 Billion Revenue
- J.B. Hunt's Q3 Earnings: Navigating Freight Industry Challenges
- Revolutionizing Digital Connectivity: HGC's Innovative DCI Clusters
- Interactive Brokers Delivers Strong Performance in Q3 2024
- RaySearch Laboratories Expands Reach with New Agreements
- U.S. Bancorp Third Quarter Earnings Surpass Estimates
- Jefferies Upgrades HDFC AMC Price Target on Strong QAAUM Growth
- Jefferies Boosts Brookdale with Buy Rating Amid Strong Trends
- Coty Inc Faces Adjustments Amid Market Challenges Ahead
- Matador Resources Boosts Dividend Amid Financial Strength
- Qualcomm Battles New Challenges as Citi Issues Warning
- Market Movement Insights: Nifty 50 and Sector Updates
- Medallion Financial Corp. Prepares for 2024 Earnings Announcement
- Harnessing AI for Growth: Ciena and NetApp's Strategies
- Parsons Corporation Secures Major Contracts for Transport Revamp
- Immuron CEO Discusses Innovations in Healthcare Conference
- MADD Canada Launches New Program for Newfoundland Students
- Why Amazon (NASDAQ: AMZN) is a Strong Buy Right Now
- Norsk Hydro's Strategic Share Buyback Program Update
- Prepare for Market Changes with Essential Investment Strategies
- Knexus Secures DLA Contract for Innovative GenAI Solutions
- Navigating Market Trends: Insights on Global Economy Today
- Gilat Satellite Networks' Participation in Key Investor Conference
- Modified Starch Market to Reach $28.9 Billion by 2034
- Exploring the Global Impact of Jingfang Herbal Formulas
- Forecasting Growth in the Marine Buoy Market By 2034
- Nanjing Medical University Marks Milestone with Celebrations
- Projected Growth of Fish Sauce Market to $29.43 Billion by 2032
- Government's New Initiatives for Housing Development Updates
- Significant New Gold Intercepts Mark Progress for Nova Minerals
- Midwest Rentals Surge Amid Southern Rental Market Decline
- Kraken Robotics Secures $13 Million in Subsea Battery Orders
- O3 Mining Initiates Normal Course Issuer Bid for Share Value
- Taboola to Announce Q3 2024 Earnings: Conference Call Details
- Canadians Alter Holiday Spending Trends Amid Inflation Woes
- KITS Eyecare Achieves Record Sales Amid Growing Demand